Ariane Biebl
Ariane Biebl has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Klaus Schmitt
Children's Hospital, Department of Paediatrics, Krankenhausstr. 26-30, 4020 Linz, Austria
5 shared publicationsDieter Furthner
Children's Hospital, Department of Paediatrics, Krankenhausstr. 26-30, 4020 Linz, Austria
3 shared publicationsBrigitte Povysil
Children's Hospital, Department of Paediatric Radiology, Krankenhausstr. 26-30, 4020 Linz, Austria
2 shared publicationsAndrea Grillenberger
Children’s Hospital
1 shared publicationAndrea Preisinger
1 shared publicationAstrid Eisenkölbl
1 shared publication
Latest Publications
- 1 May 2015
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 19 (3) , 349-353
Prospective analysis on brain magnetic resonance imaging in children
- 1 May 2015
- Published by Elsevier in European Journal of Paediatric Neurology
- Vol. 19 (3) , 349-353
Prospective analysis on brain magnetic resonance imaging in children
- 1 March 2014
- Published by Wolters Kluwer Health in Pediatric Emergency Care
- Vol. 30 (3) , 185-187
Status Epilepticus, Cardiac Resuscitation, and Posterior Reversible Encephalopathy Syndrome After Ingestion of Viscous Lidocaine
Ingestion of viscous lidocaine in children can lead to potentially lethal neurologic and cardiac effects. We report the case of a 2-year-old boy who developed posterior reversible encephalopathy syndrome 2 days after unobserved ingestion of about 500 mg viscous lidocaine (40 mg/kg of bodyweight). Initially, the child presented with convulsive status epilepticus and subsequent cardiac arrest necessitating cardiopulmonary resuscitation for eight minutes. After 2 days of full recovery, the child presented with progressive disorientation, dizziness, and visual neglect. Lasting for 2 days, these symptoms finally disappeared completely. Combined with the findings on cerebral magnetic resonance imaging, this episode was interpreted as posterior reversible encephalopathy syndrome. Two weeks after the ingestion, no neurologic and visual abnormalities were found. Viscous lidocaine is prescribed routinely for dentition or other painful lesions in the oral cavity in children. Despite the potential hazardousness of the drug, packaging of viscous lidocaine is not childproof. Therefore, physicians have to instruct the parents carefully to minimize the risk of overuse or accidental ingestion. In general, the use of viscous lidocaine should be limited.
- 1 March 2014
- Published by Wolters Kluwer Health in Pediatric Emergency Care
- Vol. 30 (3) , 185-187
Status Epilepticus, Cardiac Resuscitation, and Posterior Reversible Encephalopathy Syndrome After Ingestion of Viscous Lidocaine
Ingestion of viscous lidocaine in children can lead to potentially lethal neurologic and cardiac effects. We report the case of a 2-year-old boy who developed posterior reversible encephalopathy syndrome 2 days after unobserved ingestion of about 500 mg viscous lidocaine (40 mg/kg of bodyweight). Initially, the child presented with convulsive status epilepticus and subsequent cardiac arrest necessitating cardiopulmonary resuscitation for eight minutes. After 2 days of full recovery, the child presented with progressive disorientation, dizziness, and visual neglect. Lasting for 2 days, these symptoms finally disappeared completely. Combined with the findings on cerebral magnetic resonance imaging, this episode was interpreted as posterior reversible encephalopathy syndrome. Two weeks after the ingestion, no neurologic and visual abnormalities were found. Viscous lidocaine is prescribed routinely for dentition or other painful lesions in the oral cavity in children. Despite the potential hazardousness of the drug, packaging of viscous lidocaine is not childproof. Therefore, physicians have to instruct the parents carefully to minimize the risk of overuse or accidental ingestion. In general, the use of viscous lidocaine should be limited.
- 1 September 2013
- Published by Elsevier in Pediatric Neurology
- Vol. 49 (3) , 178-181
Facial Nerve Paralysis in Children: Is It as Benign as Supposed?
- 1 September 2013
- Published by Elsevier in Pediatric Neurology
- Vol. 49 (3) , 178-181
Facial Nerve Paralysis in Children: Is It as Benign as Supposed?
- Open Access
- 7 October 2009
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (10) , e7374
CD14 C-159T and Toll-Like Receptor 4 Asp299Gly Polymorphisms in Surviving Meningococcal Disease Patients
Carriage of Neisseria meningitidis occurs approximately in 10% of the population, onset of invasive meningococcal disease (IMD) cannot be predicted and differs between ages. It remains unclear, which host factors determine invasion of the bloodstream by the bacteria. Innate immunity has a very important role in the first recognition of invading pathogens. The functional single nucleotide polymorphisms (SNPs) CD14 C-159T and toll-like receptor 4 (TLR4) Asp299Gly have been associated with the risk of gram-negative infections. However, their role in development of IMD still remains unclear. Our aim was to investigate the influence of CD14 C-159T and TLR4 Asp299Gly polymorphisms on the risk of IMD. It was a retrospective case control study. Surviving Austrian meningococcal disease patients were enrolled by sending buccal swabs for DNA analysis. 185 cases with a proven meningococcal infection and 770 healthy controls were enrolled. In surviving meningococcal disease patients DNA analysis of CD14 C-159T and TLR 4 Asp299Gly polymorphisms was performed, as they are part of the innate immune response to bacterial determinants. CD14 C-159T and TLR4 Asp299Gly SNPs were not significantly associated with the presence of IMD when compared to healthy controls. The odds ratio for CD14 C-159T SNP was 1.14 (95% confidence interval (CI) 0.91–1.43; p = 0.266). In TLR4 Asp 299 Gly SNP the odds ratio was 0.78 (CI 0.47–1.43; p = 0.359). We could not observe a significant influence of CD14 C-159T and TLR4 Asp299Gly polymorphisms on the risk of developing IMD in surviving meningococcal disease patients. To our knowledge, this is the first study investigating the influence of the CD14 C-159T SNP on the susceptibility to IMD.
- 7 October 2009
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (10) , e7374
Open AccessCD14 C-159T and Toll-Like Receptor 4 Asp299Gly Polymorphisms in Surviving Meningococcal Disease Patients
Carriage of Neisseria meningitidis occurs approximately in 10% of the population, onset of invasive meningococcal disease (IMD) cannot be predicted and differs between ages. It remains unclear, which host factors determine invasion of the bloodstream by the bacteria. Innate immunity has a very important role in the first recognition of invading pathogens. The functional single nucleotide polymorphisms (SNPs) CD14 C-159T and toll-like receptor 4 (TLR4) Asp299Gly have been associated with the risk of gram-negative infections. However, their role in development of IMD still remains unclear. Our aim was to investigate the influence of CD14 C-159T and TLR4 Asp299Gly polymorphisms on the risk of IMD. It was a retrospective case control study. Surviving Austrian meningococcal disease patients were enrolled by sending buccal swabs for DNA analysis. 185 cases with a proven meningococcal infection and 770 healthy controls were enrolled. In surviving meningococcal disease patients DNA analysis of CD14 C-159T and TLR 4 Asp299Gly polymorphisms was performed, as they are part of the innate immune response to bacterial determinants. CD14 C-159T and TLR4 Asp299Gly SNPs were not significantly associated with the presence of IMD when compared to healthy controls. The odds ratio for CD14 C-159T SNP was 1.14 (95% confidence interval (CI) 0.91–1.43; p = 0.266). In TLR4 Asp 299 Gly SNP the odds ratio was 0.78 (CI 0.47–1.43; p = 0.359). We could not observe a significant influence of CD14 C-159T and TLR4 Asp299Gly polymorphisms on the risk of developing IMD in surviving meningococcal disease patients. To our knowledge, this is the first study investigating the influence of the CD14 C-159T SNP on the susceptibility to IMD.
- 1 March 2009
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 5 (3) , 171-174
Fatal Epstein–Barr virus encephalitis in a 12-year-old child: an underappreciated neurological complication?
Biebl et al. describe the case of a 12-year-old boy who presented with fever, malaise and fatigue, and was diagnosed with Epstein–Barr virus (EBV) encephalitis when his cerebrospinal fluid tested positive for EBV. Despite intensive care and antiviral treatment, the patient died 1 month after the initial presentation. The authors suggest that EBV encephalitis should be considered in the differential diagnosis when a young patient presents with acute neurological illness of uncertain etiology. Background A 12-year-old boy presented to a community hospital with fever, malaise and fatigue. A polymerase chain reaction test of the cerebrospinal fluid was positive for Epstein–Barr virus. Despite intensive care treatment and antiviral drugs, the patient died 1 month after his initial presentation. Investigations Physical examination, polymerase chain reaction analysis of the cerebrospinal fluid, brain MRI, immunohistochemistry and molecular biological investigations of postmortem brain samples. Diagnosis Epstein–Barr Virus encephalitis. Management Aciclovir, intensive care treatment with intubation, sedation, antiepileptic drugs.
- 1 March 2009
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 5 (3) , 171-174
Fatal Epstein–Barr virus encephalitis in a 12-year-old child: an underappreciated neurological complication?
Biebl et al. describe the case of a 12-year-old boy who presented with fever, malaise and fatigue, and was diagnosed with Epstein–Barr virus (EBV) encephalitis when his cerebrospinal fluid tested positive for EBV. Despite intensive care and antiviral treatment, the patient died 1 month after the initial presentation. The authors suggest that EBV encephalitis should be considered in the differential diagnosis when a young patient presents with acute neurological illness of uncertain etiology. Background A 12-year-old boy presented to a community hospital with fever, malaise and fatigue. A polymerase chain reaction test of the cerebrospinal fluid was positive for Epstein–Barr virus. Despite intensive care treatment and antiviral drugs, the patient died 1 month after his initial presentation. Investigations Physical examination, polymerase chain reaction analysis of the cerebrospinal fluid, brain MRI, immunohistochemistry and molecular biological investigations of postmortem brain samples. Diagnosis Epstein–Barr Virus encephalitis. Management Aciclovir, intensive care treatment with intubation, sedation, antiepileptic drugs.
- Open Access
- 24 January 2009
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 168 (8) , 1021
Reply to correspondence letter: enema-induced severe hyperphosphatemia in children
- 24 January 2009
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 168 (8) , 1021
Open AccessReply to correspondence letter: enema-induced severe hyperphosphatemia in children
- 12 April 2008
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 168 (1) , 111-112
Enema-induced severe hyperphosphatemia in children
We report the case of a 13-year-old boy with Costello syndrome and chronic constipation who received phosphate-containing Fleet-pediatric enemas at regular intervals. The day before admission he was given four enemas for severe constipation. Within 24 h the boy had developed severe hyperphosphatemia (phosphate 17.75 mmol/L), hypertonic dehydration (sodium 171 mmol/L) and severe hypocalcemia (calcium 0.56 mmol/L). With early intervention and treatment, the child survived without sequelae. Osmotically acting hypertonic phosphate enemas may result in severe toxicity. Children with developmental delay often display bowel dysfunction and chronic constipation and are therefore high-risk patients. The accepted opinion—that these enemas are not absorbed and therefore systemically inactive—is not true. Physicians should be aware of the potentially lethal complications of this treatment, which is part of everyday clinical practice.
- 12 April 2008
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 168 (1) , 111-112
Enema-induced severe hyperphosphatemia in children
We report the case of a 13-year-old boy with Costello syndrome and chronic constipation who received phosphate-containing Fleet-pediatric enemas at regular intervals. The day before admission he was given four enemas for severe constipation. Within 24 h the boy had developed severe hyperphosphatemia (phosphate 17.75 mmol/L), hypertonic dehydration (sodium 171 mmol/L) and severe hypocalcemia (calcium 0.56 mmol/L). With early intervention and treatment, the child survived without sequelae. Osmotically acting hypertonic phosphate enemas may result in severe toxicity. Children with developmental delay often display bowel dysfunction and chronic constipation and are therefore high-risk patients. The accepted opinion—that these enemas are not absorbed and therefore systemically inactive—is not true. Physicians should be aware of the potentially lethal complications of this treatment, which is part of everyday clinical practice.